



GMMM Interface Prescribing
Subgroup



Agenda

13th August 2015, 1pm-3pm

HMR CCG

Room G10, Number One Riverside, Smith St. Rochdale OL16 1XU

[Declarations of Interest](#) (new declarations only)

Apologies:

	ENC
1) Draft Minutes of 9th July 2015	Item 1
2) Matters Arising <ul style="list-style-type: none"> a) RAG List Recommendations from April meeting (Chapter 1 & 8) – now GMMM approved b) Shared care protocols for paediatric ADHD, Long acting antipsychotic injections, hydroxycarbamide, and growth hormone in adults – now GMMM approved c) RAG List Recommendations from May meeting – comments received d) RAG List Recommendations from June meeting – comments received e) RAG List Recommendations from July meeting – currently out for comment until 3rd Sept 2015. f) Inclusion of Grey/DNP List drugs on RAG list g) Amiodarone in paediatrics RAG status 	Item 2c Item 2d
3) Updated Terms of Reference including voting and appeals process	Item 3
4) Interface processes for RAG list and Shared Care Protocols	Item 4a Item 4b Item 4c Item 4d Item 4e
5) Guidelines on defining RED/AMBER/GREEN MEDICINE Status - updated	Item 5
6) Clarification of 6mg dose of melatonin in melatonin SCP	Item 6
7) Apraclonidine eye drops	Item 7
8) Drugs requiring a review of RAG status <ul style="list-style-type: none"> • Amantadine for MS • Ezetimibe • Pregabalin in neuropathic pain • Acetazolamide for idiopathic intracranial hypertension • Naltrexone for opioid detoxification 	Item 8

<p>9) New Drugs from NTS and Formulary Subgroup Requiring a RAG Status</p> <ul style="list-style-type: none"> • Simbrinza® (Brinzolamide/Brimonidine) eye drops • Secukinumab for moderate to severe plaque psoriasis – suggest RED. • Apremilast for moderate to severe chronic plaque psoriasis and active psoriatic arthritis – suggest RED. 	
<p>10) Share Care Protocols for approval – final versions for GMMMG</p> <ul style="list-style-type: none"> • Mercaptopurine and Azathioprine for Inflammatory bowel disease • Azathioprine for the treatment of chronic inflammatory bowel disease (unlicensed use) in paediatric patients • SSRIs in children and adolescents for OCD & BDD • SSRIs in children and adolescents for depression • SSRIs in children and adolescents for anxiety • Antipsychotics for schizophrenia in children & adolescents • Antipsychotics for OCD in children & adolescents • Antipsychotics for Bipolar in children & adolescents 	<p>Item 10a Item 10b Item 10c Item 10d Item 10e Item 10f Item 10g Item 10h</p>
<p>11) Nalmefene SCP – 2nd draft</p>	<p>Item 11</p>
<p>12) Progress with GMMMG versions of SCPs as of July 2015</p>	<p>Item 12</p>
<p>13) NOAC alert card</p>	<p>Item 13</p>
<p>14) Monitoring of Drugs in Primary Care</p>	<p>Item 14</p>
<p>15) Shared Care Protocols – drafts to go out to CCG/Trusts for comment</p> <ul style="list-style-type: none"> • Ethinylestradiol for pubertal induction • Ciclosporin for paediatric nephrotic syndrome • Riluzole 	<p>Item 15a Item 15b Item 15c Item 15d</p>
<p>16) Declarations of Interest 2015/16 – now due</p>	<p>Item 16</p>
<p>17) Updates from other groups</p>	
<p>a) Formulary Subgroup (verbal)</p>	
<p>b) New Therapies Subgroup (verbal)</p>	
<p>c) GMMMG (verbal)</p>	
<p>18) AOB</p>	
<p>Date of Next Meeting: 10th September 2015, 1pm-3pm, Dawes Family Practice, 83 Spotland Road, Rochdale, OL12 6RX</p>	